ReviewLife (Basel, Switzerland)2022
Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice.
Review in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Efficacy and safety of antibiotic regimens forFrontiers in medicine · 2026Pooled it
- Efficacy and safety of potassium-competitive acid blockers in eradicatingCaspian journal of internal medicine · 2026Review
- Development of a multi-epitope vaccine against Helicobacter pylori using a novel saRNA technology through an immunoinformatics approach.Scientific reports · 2025Article
- Co-Infection Dynamics ofInternational journal of molecular sciences · 2025Review
- Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori.The Journal of antimicrobial chemotherapy · 2025Article
- Challenges and Prospects for Eradication ofPathogens (Basel, Switzerland) · 2025Review
- Anti-urease therapy: a targeted approach to mitigating antibiotic resistance in Helicobacter pylori while preserving the gut microflora.Gut pathogens · 2025Review
- Clinical Effectiveness of Penicillin-Free Therapies in First-Line and Rescue Treatments forAntibiotics (Basel, Switzerland) · 2025Review
- HalogenatedACS medicinal chemistry letters · 2025Article
- Exploring the bioactive compounds ofFrontiers in cellular and infection microbiology · 2025Article
- Addressing the global challenge ofGut microbes reports · 2025Article
- Unravelling Peptic Ulcers: Comprehensive Insights into Etiology, Diagnosis, Screening Techniques, and Treatment.Current pharmaceutical design · 2025Review
- Comparative Efficacy of Azithromycin and Clarithromycin in the Management of Helicobacter pylori Infection.Cureus · 2024Article
- Optimization ofInternational journal of molecular sciences · 2024Article
- Liposomal Drug Delivery againstPharmaceutics · 2024Article
- Antimicrobial susceptibility of clinicalMicrobiology spectrum · 2024Article
- Artesunate Dry Emulsion Formulation Combined with Antibiotics for Treatment ofInternational journal of molecular sciences · 2023Article
- Editorial:Frontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhen prescribing antibiotics, infection eradication rates, local resistance rates, and cost should be among the most essential considerations.
methodsThis was a narrative review. The sources for this review are as follows: searching on PubMed, Google Scholar, Medline, and ScienceDirect; using keywords:
resultsMultiple antibiotics are prescribed as part of the regimen to thwart high resistance rates. This can lead to unwanted adverse reactions and adherence issues, due to the amount and timing of medication administration, which also may contribute to resistance. Single-capsule combination capsules have reached the market to ease this concern, but brand-only may be problematic for patient affordability. Due to the previously mentioned factors, effectiveness and affordability must be equally considered.
conclusionsThis review will utilize guidelines to discuss current treatment options and give cost considerations to elicit the most effective regimen for the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.